Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.76 |
| ▸ | RAF1 | P04049 | 17/20 | 0.76 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | ERN1 | O75460 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.58 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.58 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20998751 | 0.92 | BRAF (0.83) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL21922370 | 0.90 | BRAF (0.79) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL21922367 | 0.88 | BRAF (0.78) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL21152531 | 0.87 | BRAF (0.83) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL21152559 | 0.87 | BRAF (0.75) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL21923134 | 0.86 | BRAF (0.79) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL20998717 | 0.86 | BRAF (1.00) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL21153280 | 0.86 | BRAF (0.81) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL21923137 | 0.85 | BRAF (0.80) | BRAFRAF1EGFRERN1ABL1 | |
| SCHEMBL20998760 | 0.85 | BRAF (0.57) | BRAFRAF1EGFRFLT3MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332479-B2 | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-05-17 | — | — | US | disclosed |
| US-20200131199-A1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-04-30 | — | — | US | disclosed |
| US-10570155-B2 | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-02-25 | — | — | US | disclosed |
| US-20190211032-A1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131199-A1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | TPMT, MYD88, IDO1 | BRAF 159/4885RAF1 978/4885EGFR 2278/4885 |
| US-10570155-B2 | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | TPMT, MYD88, IDO1 | BRAF 159/4885RAF1 978/4885EGFR 2278/4885 |
| US-11332479-B2 | Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same | TPMT, MYD88, IDO1 | BRAF 159/4885RAF1 978/4885EGFR 2278/4885 |
| US-20190211032-A1 | IMIDAZOOXAZOLE DERIVATIVE HAVING ANTITUMOR EFFECT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | TPMT, MYD88, IDO1 | BRAF 159/4885RAF1 978/4885EGFR 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.